UroAlert - GU Oncology Weekly

September 25, 2025

Videos

Peer-to-Peer Clinical Conversations

Addressing Limitations in Current Toxicity Reporting for Bladder Cancer Therapies - Shilpa Gupta

Shilpa Gupta

Ashish Kamat and Shilpa Gupta address the need for improved toxicity grading systems for systemic therapy-related bladder effects.

Multimodal AI Test Predicts Prostate Cancer Metastasis and Treatment Response - Timothy Showalter

Tim Showalter

Leslie Ballas speaks with Timothy Showalter about a multimodal artificial intelligence-based prostate cancer test.

Beyond the Abstracts

Clinical Trial Protocol for prePSMA: A Multicenter, Randomized, Noninferiority Trial of Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as Triage for Extended Pelvic Lymph Node - Beyond the Abstract

Association of Elevated Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and De Ritis Ratios with Major Complications after Surgery for Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

ERAS 2025: ERAS® Beyond Cystectomy Standardizing Pathways on Focal Therapy for Prostate Cancer: How Can We Manage and Reduce Complications?

ERAS 2025: Nutritional Strategies in ERAS®

SCS AUA 2025: Contemporary Outcomes for Radical Nephrectomy with Inferior Vena Cava Thrombectomy in the Era of Pre-Operative Immunotherapy

SCS AUA 2025: Underreporting of CIS in Patients with High-Grade Papillary NMIBC

SCS AUA 2025: Pre-Clinic Educational Information’s Effect on Anxiety in Patients with Renal Masses

Physician-Scientist Review Articles

Neoadjuvant Sintilimab with Gemcitabine and Cisplatin for Muscle-Invasive Bladder Cancer - Expert Commentary

Treatment Outcomes after Progression on Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-γ profiling.

Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer.

Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study.

A Phase 1b Study of Avelumab Plus Bacillus Calmette-Guérin in Patients With Nonmuscle-Invasive Bladder Cancer

Evaluating Surrogate Endpoints for Adjuvant Chemotherapy of Bladder Cancer - Expert Commentary

Applicability of the European Association of Urology 2021 Prognostic Model for Non-muscle-invasive Bladder Cancer in a Swedish Population-based Cohort.

Genetic susceptibility and environmental risk factors in bladder cancer: Evidence from the UK biobank.

Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.

The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG): A

Targeted therapies for Bacillus Calmette-Guerin unresponsive nonmuscle-invasive bladder cancer: a narrative review.

Development and analytical validation of a multiplex diagnostic qPCR-array as a potential application in predicting the response to neoadjuvant chemotherapy in muscle invasive bladder cancer.

Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study.

Penile & Urethral Cancers

Psychometric properties and content of instruments for assessing penile cancer patients' quality of life: A systematic review.

Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer: The Nonrandomized HERCULES (LACOG 0218) Clinical Trial.

The Swedish national guidelines on penile cancer.

Expression profile of small nucleolar RNAs (snoRNAs) in penile cancer.

Renal Cancer

[99mTc]Tc-sestamibi SPECT/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study).

An immunometabolism-related signature for renal clear cell carcinoma diagnosis and therapeutic target.

Synchronous multiple meningiomas and renal cell carcinoma metastasis to the brain in a 68Ga-DOTATATE scan: illustrative case.

Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma.

Titrating Cabozantinib in Metastatic Renal Cell Carcinoma Patients Using Goldilocks Principle: A Real-World Evidence Study.

Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell Carcinoma.

Reticulocalbin-1 in clear cell renal cell carcinoma: clinical and functional evidence for its role as a biomarker and potential therapeutic target.

HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors.

Identification of CD159A as a prognostic and immune biomarker in kidney renal clear cell carcinoma.

Comparative analysis of clinicopathological characteristics and prognostic outcomes in fumarate hydratase-deficient renal cell carcinoma versus high-grade papillary renal cell carcinoma.

Association of Elevated Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and De Ritis Ratios with Major Complications after Surgery for Renal Cell Carcinoma - Beyond the Abstract

Prostate Cancer

National and Location-Specific Medicare Physician Fee Reimbursement Trends in Urologic Oncology From 2002 to 2024.

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

First evidence of Retzius-sparing robot-assisted radical prostatectomy with the Versius robotic surgical system.

Perioperative outcomes comparing the DaVinci 5 with DaVinci Xi in patients undergoing robotic-assisted radical prostatectomy.

Adverse events during radical prostatectomy and their association with recurrence and death.

Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden.

177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.

Managing Robotic Radical Prostatectomy in Men with Penile Prosthesis: Surgical Tech-nique, Outcomes, and Literature Review.

Review of Transperineal and Transrectal Prostate Biopsy Outcomes - Beyond the Abstract

Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score.

Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [177Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360° Cadmium-Zinc-Telluride SPECT.

Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.

Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.

Emerging tools for the early detection of prostate cancer.

Transperineal 3T MRI-guided and transrectal MRI-ultrasound fusion prostate biopsies: Do lesion location and size impact diagnostic yield?

Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.

Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.

Prostate-Specific Antigen Levels Among Participants Receiving Annual Testing.

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.

Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer.

Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer.

Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry.

Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer.

PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy.

Re-irradiation in patients affected by prostate cancer and relapsing after previous definitive or postoperative radiotherapy. An international registry based study on behalf of Italian association of radiotherapy and clinical oncology (AIRO). (RE-START).

Radiomics Features from Different Prostatic Zones on 18F-PSMA-1007 PET/CT for Predicting Persistent PSA in Prostate Cancer Patients: A Multicenter Study.

The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials.

Training With Local Data Remains Important for Deep Learning MRI Prostate Cancer Detection.

[68Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.

The Complex Interplay of Modifiable Risk Factors Affecting Prostate Cancer Disparities in African American Men - Beyond the Abstract

Clinical Trial Protocol for prePSMA: A Multicenter, Randomized, Noninferiority Trial of Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as Triage for Extended Pelvic Lymph Node - Beyond the Abstract

Role of the Stockholm3 Test in Guiding Confirmation Biopsy Decisions for Patients with Prostate Cancer on Active Surveillance - Beyond the Abstract

BCL2 Drives Castration Resistance in Castration-Sensitive Prostate Cancer by Orchestrating Reciprocal Crosstalk Between Oncogenic Pathways - Beyond the Abstract

Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy - Beyond the Abstract

Comparison of Diagnostic Performance Between Manual Diagnosis Following PROMISE V2 and aPROMISE Utilizing Ga/F‑PSMA PET/CT - Beyond the Abstract

Upper Tract Tumors

Waiting time in diagnosis and extirpative surgery and association with survival and stage progression in upper tract urothelial carcinomas.

The utility of preoperative diagnostics in patients undergoing radical nephroureterectomy for suspected upper tract urothelial carcinoma: Can we justify treatment without prior histologic confirmation?

Testicular Cancer

Exercise, diet and psychological support for patients with testicular cancer.

Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma.

Role of Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Seminoma: Recommendations from the European Association of Urology Guidelines Panel on Testicular Cancer.

Beyond Germ Cell Tumors: Focus on Leydig Cell Neoplasms from a Single-Center Experience - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC